anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A composition containing urushiol-removed Rhus verniciflua Stokes fermentation extract is provided to promote hair growth without irritation to scalp and to prevent alopecia. CONSTITUTION: A method for manufacturing hair cosmetic composition comprises: a step of preparing Rhus verniciflua Stokes extract using purified water, methanol, ethanol, glycerin, ethyl acetate, butylene glycol, propylene glycol, dichloromethane or hexane at 80-100 Deg. C.; and a step of inoculating Grifola frondosa HB0071(KCTC 10337BP) to the extract and fermenting the extract at 4-40 Deg. C. for 1-4 days to prepare Rhus verniciflua Stokes fermentation extract. The hair cosmetic composition contains 0.01-30 wt% of the Rhus verniciflua Stokes fermentation extract as an active ingredient. The hair cosmetic composition is manufactured in the form of a hair tonic, hair lotion, hair cream, hair spray, hair mousse, hair gel, hair conditioner, hair shampoo, hair rinse, hair pack, or hair treatment.
The invention discloses an application of a recombinant human cell globin on preparation of a fatty liver medicament. Through building an alcoholic liver rat model, subcutaneous injection is carried out for treatment according to the dose of 3mg/Kg of rhCYGB. An experiment shows that a recombinant human cell globin medicament is non-toxic; and in comparison with a model control group, an rhCYGB treatment group is remarkably improved, fat droplets are obviously reduced, and hepatic cords are levelly arranged. A reduced glutathione treatment group still has obvious fatty degeneration, and liver cells are lightly swollen. The rhCYGB has better efficacy in the treatment of an alcoholic fatty liver than the reduced glutathione. The recombinant human cell globin has the advantages of low toxicity, safety and effectiveness on fatty livers, and especially the alcoholic fatty liver.
PURPOSE OF REVIEW: The number of patients on the liver transplant waitlist continues to grow and far exceeds the number of livers available for transplantation. Normothermic machine perfusion (NMP) allows for ex-vivo perfusion under physiologic conditions with the potential to significantly increase organ yield and expand the donor pool.
RECENT FINDINGS: Several studies have found increased utilization of donation after cardiac death and extended criteria brain-dead donor livers with implementation of NMP, largely due to the ability to perform viability testing during machine perfusion. Recently, proposed viability criteria include lactate clearance, maintenance of perfusate pH more than 7.2, ALT less than 6000 u/l, evidence of glucose metabolism and bile production. Optimization of liver grafts during NMP is an active area of research and includes interventions for defatting steatotic livers, preventing ischemic cholangiopathy and rejection, and minimizing ischemia reperfusion injury.
SUMMARY: NMP has resulted in increased organ utilization from marginal donors with acceptable outcomes. The added flexibility of prolonged organ storage times has the potential to improve time constraints and transplant logistics. Further research to determine ideal viability criteria and investigate ways to optimize marginal and otherwise nontransplantable liver grafts during NMP is warranted.
Using FIGO recommended preeclampsia screening model for the first-trimester which combined maternal risk factors, mean arterial pressure, placental growth factor, uterine artery pulsatility index to evaluate pregnant's risk for preeclampsia. Risk value\<1/100 is defined as screened low risk.
Participants will be enrolled into 3 cohorts. In the treatment-naive cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior ibrutinib cohort, approximately 40 participants with Prior ibrutinib therapy will be enrolled.
Naltrexone has been established as an efficacious medication to treat alcohol dependence but studies thus far have focused mostly on the acute phase of treatment rather than long-term management and have not offered alternative treatment strategies when patients do not respond to an initial course of naltrexone. For these initial non-responders to naltrexone, it is unclear what adjustments to treatment should be made to increase the likelihood of treatment success. We are unaware of previous research focused specifically on naltrexone non-response. Pilot data from ongoing trials at our center, however, suggest that up to a third of patients fail to respond to naltrexone. Moreover, these non-responsive patients go on to have the worst outcomes during the next 6 months of treatment if maintained on the same combination of naltrexone and medication management (MM). We propose to augment medication management with a combination of motivational enhancement therapy and cognitive behavioral therapy (combined behavioral intervention - CBI) and to test the benefits of continued/discontinued treatment with naltrexone in a randomized placebo-controlled trial. Clinical strategies for second line treatments often favor switching treatments rather than augmentation. However, there may be synergies between naltrexone and CBI that were not apparent with medication management. Specifically, CBI may have advantages in motivating patients to greater medication adherence (a leading cause of naltrexone treatment failure) and CBI may address psychosocial factors that limited or attenuated the effects of naltrexone.
An embodiment of an ingestible device for delivering a therapeutic agent includes a swallowable housing and a delivery mechanism within the housing. The delivery mechanism includes an expandable shell. The delivery mechanism is capable of being triggered in situ within a Gastrointestinal (GI) tract of the body to expand a plurality of regions of the expandable shell to an expanded state at a delivery location within the body. The plurality of regions includes a head region, a tail region, and a retaining region, and a protective recess is defined between the head region and the tail region, the retaining region being located within the protective recess. The size of the holding zone when inflated is smaller than the size of the head zone when inflated and smaller than the size of the tail zone when inflated. The ingestible device includes a molding composition disposed at the retention zone.
BACKGROUND: Research on the cardiovascular toxicity of angiogenesis inhibitors among patients with cancer in Taiwan is lacking. This observational study explored the risk of major adverse cardiovascular events (MACEs) associated with angiogenesis inhibitors in Taiwan.
METHODS AND RESULTS: We conducted a nested case-control study using the TCR (Taiwan Cancer Registry) linked with the Taiwan National Insurance Claim Database. We matched every case with 4 controls using risk-set sampling by index date, age, sex, cancer type, and cancer diagnosis date. Conditional logistic regression was used to evaluate the risks of MACEs and different cardiovascular events using propensity score adjustment or matching. Sensitivity analyses were used to evaluate the risks matched by cancer stages or exposure within 1 year. Among a cohort of 284 292 after the exclusion of prevalent cases, the incidences of MACEs among the overall cohort and those exposed to angiogenesis inhibitors were 22.5 and 32.5 events per 1000 person-years, respectively. We matched 17 817 cases with 70 740 controls, with a mean age of 74.9 years, and 56.8% of patients were men. After propensity score adjustment, angiogenesis inhibitors were associated with increased risks of MACEs (odds ratio, 4.56; 95% CI, 1.78-11.59). Significantly increased risks were noted for heart failure hospitalization, myocardial infarction, cerebrovascular accident, and venous thromboembolism, but not for new-onset atrial fibrillation. Similar results were observed after matching by cancer stage or restriction of 1-year exposure.
CONCLUSIONS: Angiogenesis inhibitors were associated with increased risks of MACEs among patients with various malignancies in Taiwan but were not associated with new-onset atrial fibrillation.
BACKGROUND: Cerebral palsy (CP) represents for children an important problem of health and affects roughly 2 per 1000 live births and is the most common pediatric developmental motor disability. Therefore, the purpose of this study was to determine the prevalence, type and severity of malocclusion and oral habits in children with Cerebral Palsy (CP) and to compare them with a control group of healthy children in Sana'a city.
MATERIALS AND METHODS: A prospective, case-control study was made of two groups, a cerebral palsy and a control group. The study population consisted of 60 children who had CP, and a control group of 60 matched children with no physical or mental disabilities. Data were collected using a questionnaire and assessment for malocclusion was done clinically. The patients were compared with equal number of age-matched controls. The inclusion criteria were individuals aged over 6 years; absence of previous orthodontic treatment; no missing permanent first molars.
RESULTS: Results showed an increased prevalence of malocclusion in children with cerebral palsy. Molar class II relationship was statistically higher in cerebral palsy children than healthy control (P = 0.001). Cerebral palsied children are likely to have a significantly increased protrusion of the anterior teeth (P < 0.001) when compared with normal children. Mouth breathing and Tongue thrust. Habits were significantly higher in the CP group (p = 0.0001) when compared with normal children.
CONCLUSION: The prevalence of malocclusion was higher in children with Cerebral palsy than in normal children, and the present study concludes that in children with Cerebral Palsy, more oral Habits problems due to oral motor dysfunctions are common and problems of mouth breathing and Tongue thrust produce different malocclusion and poor oral hygiene complications in these children.
Successfully implementing a SFSO-MPI protocol requires a validated pre-screening tool and a proven imaging protocol that aids the physician in reporting the study with confidence. The investigator's previous study, entitled "The feasibility of Stress-First/Stress-Only Myocardial Perfusion Imaging to reduce patient radiation exposure in a selected subset of patients undergoing testing in a tertiary care facility (SFSO-MPI)", was designed to validate a pre-screening tool developed by Duvall et al. In the investigator's population the tool demonstrated sensitivity and specificity (95% CI) of 0.79 (0.74-0.83) and 0.55 (0.48-0.62) (unpublished data). The sensitivity was lower than previous published. However the investigators noted that a greater proportion of participants were classified as abnormal (55% vs 31 and 36% in the two cohorts described by Duvall et al) and a high number of patients (15%) were reported as having equivocal stress images. These factors may have affected the sensitivity of the pre-screening tool. A greater proportion of the investigator's participants would then have required a rest study for proper interpretation of the test. Additional imaging increases the patients' radiation exposure and time requirement for the study and affects the proper allocation of department resources.

The department routinely images patients in only the supine position. The implementation of routine combined supine/prone imaging is expected to decrease image artifacts which may reduce the number of studies reported as equivocal. If combined supine/prone imaging is successful in changing the interpretation of a significant proportion of equivocal stress studies to normal, then the need for rest imaging will be obviated in a larger group of patients, resulting in reduced radiation dose to patients and medical staff, better laboratory efficiency due to faster throughput, reduced time commitment for patients and lower radiopharmaceutical cost. This change to practice will also further aid meeting the American Society of Nuclear Cardiology (ASNC) goal of no more than 9mSv patient exposure in 50% of studies.
The utility model discloses a medicine suspension agent for treating and preventing diseases or adjusting the physiological function thereof for the skin of a human body or an animal body in a non-contact state by medicine information. The basic structure of the medicine suspension agent is formed by combining a medicine storing warehouse (1), a container (4) and a connecting piece (5). The content (2) is medicine with pharmacological activity. When the medicine suspension agent is in treatment, no medicine substance enters the human body or the animal body, no safety problem can occur, and the phenomena of the stimulation and the pass effect of an oral preparation to the gastrointestinal tract, the pain of the injection, cross infection risk and injection and infusion reaction, damage of the stimulation of transdermal patches to the skin and damage of adhesives to the skin and the like are avoided. The medicine suspension agent can be repeatedly used, thus greatly reducing the consumption of medicines, saving medicine resources, reducing the environmental pollution caused by the pharmaceutical industry, and being beneficial to ecological protection. The medicine suspension agent is simple, convenient and safe in use, and is more applicable to treatment of old, weak, children and mentally retarded patients and the animals.
Table 4 lists treatment-emergent adverse reactions that occurred in at least 1% of adults treated with 200 to 400 mg/day topiramate in controlled trials that were numerically more common at this dose than in the patients treated with placebo. In general, most patients who experienced adverse reactions during the first eight weeks of these trials no longer experienced them by their last visit. Table 7 lists treatment-emergent adverse reactions that occurred in at least 1% of pediatric patients treated with 5 to 9 mg/kg topiramate in controlled trials that were numerically more common than in patients treated with placebo.

The prescriber should be aware that these data were obtained when topiramate was added to concurrent antiepileptic drug therapy and cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. Inspection of these frequencies, however, does provide the prescribing physician with a basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.
The sociodemographic characteristics of the subjects were evaluated with the case report form, the balance and fall risks, the Tinetti Gait and Balance Test (TGBT) and the 5-times Sit to Stand Test, while the gait speed was assessed by the Gait Speed Measurement Test (GSMT).the control group was reevaluated at the end of the 6th week after the initial evaluation. After the study was completed, training was given to the volunteers from the control group.
Approaching patients with paraproteinemic neuropathies can be challenging for the practicing neurologist, and a well-defined strategy considering specific etiologies is necessary to arrive at the correct diagnosis. In this case, a 49-year-old man presented with a 2-year history of progressive upper then lower extremity numbness, weakness, gait instability, and tremors. His examination was marked by proximal and distal symmetric upper and lower extremity weakness, large more than small-fiber sensory loss, prominent sensory ataxia, action and postural tremors, and globally absent deep tendon reflexes. His workup was notable for a chronic demyelinating sensorimotor polyradiculoneuropathy and a monoclonal immunoglobulin (Ig) M kappa gammopathy. This case highlights the approach to a patient with a rare subtype of IgM paraproteinemic neuropathy with a review of the differential diagnoses, red flag features of co-occurring hematologic disorders, and guided workup. We further discuss typical features of this rare diagnosis and therapeutic options.
Use of heparin or its salts (I) for prophylaxis and acute treatment of allergic conjunctivitis is new. Ocular antiinflammatory effect of (I) is described in Invest. Opthalmol. Vis. Sci.35, 4(1994) 1291. In a test on mice with induced allergic conjunctivitis, heparin gave considerably better results than placebo or cromoglycinic acid as prophylactic.
Female patients of childbearing age should be told about the consequences of exposure to lisinopril during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.

NOTE: As with many other drugs, certain advice to patients being treated with lisinopril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
Patients with HCC, iCC and mCRC will be treated. TheraSphere is administered in the liver through the hepatic artery. Treatment will be performed according to the Instructions for Use (IFU). Activity of administered TheraSphere is tailored in order to deliver an absorbed dose of 80 to150 gray (Gy) to the liver. Lung dose (D) will be calculated from the following formula: D=A\*(1-S)\*50/1. D=Planned dose absorbed by treated volume(Gy), A=Activity injected with microspheres (gigabequerel \[GBq\]), S=Percentage of pulmonary shunt, "1" assuming that the lung mass=1 kilograms \[kg\]). Number of treatments is up to Investigator's discretion while taking into account the cumulative dose to the liver and lung.
Visual shape discrimination is faster for objects close to the body, in the peripersonal space (PPS), compared with objects far from the body. Visual processing enhancement in PPS occurs also when perceived depth is based on 2D pictorial cues. This advantage has been observed from relatively low-level (detection, size, orientation) to high-level visual features (face processing). While multisensory association also displays proximal advantages, whether PPS influences visual perceptual learning remains unclear. Here, we investigated whether perceptual learning effects vary according to the distance of visual stimuli (near or far) from the observer, illusorily induced by leveraging the Ponzo illusion. Participants performed a visual search task in which they reported whether a specific target object orientation (e.g., triangle pointing downward) was present among distractors. Performance was assessed before and after practicing the visual search task (30 minutes/day for 5 days) at either the close (near group) or far (far group) distance. Results showed that participants that performed the training in the near space did not improve. By contrast, participants that performed the training in the far space showed an improvement in the visual search task in both the far and near spaces. We suggest that such improvement following the far training is due to a greater deployment of attention in the far space, which could make the learning more effective and generalize across spaces.
Poziotinib will be taken by the patient orally, once daily with food and a glass of water at approximately the same time. The dose will be the last dose received or at the standard starting dose of 16 mg poziotinib. If a dose is missed, it may be taken any time during the day preferably with food, but at least 8 hours prior to the next scheduled dose.
Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
The embodiment of the invention provides a medicine recommendation method, a medicine recommendation device, medicine recommendation equipment and a storage medium, and relates to the technical field of big data processing. The medicine recommending method comprises the following steps of S1, obtaining a patient medicine list. Wherein the patient drug list comprises medication lists of the target patient and other patients. And S2, selecting a plurality of other patients with similar medication lists and target patients according to the patient medicine lists, and marking the patients as similar patients. And S3, extracting the medicines which do not appear in the medicine list of the target patient in the medicine lists of the plurality of similar patients to obtain a medicine library. And S4, calculating the value of each medicine in the medicine library according to the similarity of the medicine lists of each approximate patient and the target patient and the occurrence condition of the medicines in the medicine lists of the approximate patients. And S5, generating a recommended medicine of the target patient according to the value. By acquiring recommended medicines from similar patients, medication references can be provided for doctors and patients, and the method has good practical significance.
OBJECTIVES: To evaluate the risk factors for postoperative complications in adolescents who undergo primary hypospadias repair and determine the time required for complication detection.
METHODS: Our study included patients classified as Tanner stages three to five who underwent primary hypospadias repairs at our hospital from January 2015 to August 2022. The patients' baseline information, clinical characteristics, postoperative complications, and time to complication detection were collected. Cox regression analysis, ROC curves, Kaplan-Meier survival analyses, and the Mann-Whitney U test were used.
RESULTS: The study comprised 143 patients, with a median age of 12.58 years. Postoperative complications were experienced by 66 patients. The length of the urethral defect was identified as an independent risk factor for postoperative complications. The ROC curve analysis identified 3 cm as the optimal cutoff value for the length of the urethral defect. The median time to complication detection was 30.5 days (IQR 23 to 209.25). 89.4% of the complications were identified within the first year. Patients with a urethral defect of <3 cm experienced a significantly longer time for the detection of urethral fistula compared to those with a urethral defect of ≥3 cm (p = 0.047).
CONCLUSIONS: Our data indicate that adolescents with a urethral defect ≥3 cm have a higher risk of postoperative complications. Although most complications were identified within the first year, conducting long-term follow-ups for adolescents is recommended to identify potential subsequent complications that may arise from persistent urethral alterations.
All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.